Elevation of circulating adiponectin has shown effectiveness in preventing obesity and related cardiometabolic disorders; therefore, adiponectin is considered a therapeutic target for obesity, diabetes, and endothelial dysfunction [98]. Here, ADIPOQ is linked to obesity due to melanocortin 4 receptor deficiency.